{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:36:53Z","timestamp":1778657813428,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T00:00:00Z","timestamp":1344384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2415-12-37","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T00:13:57Z","timestamp":1344384837000},"source":"Crossref","is-referenced-by-count":12,"title":["A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus"],"prefix":"10.1186","volume":"12","author":[{"given":"Theresa","family":"Dombi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth K","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla B","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,8]]},"reference":[{"issue":"2","key":"257_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-008-0111-x","volume":"30","author":"AP Adamis","year":"2008","unstructured":"Adamis AP, Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008, 30 (2): 65-84. 10.1007\/s00281-008-0111-x.","journal-title":"Semin Immunopathol"},{"issue":"4","key":"257_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11892-008-0047-5","volume":"8","author":"TW Gardner","year":"2008","unstructured":"Gardner TW, Antonetti DA: Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008, 8 (4): 263-269. 10.1007\/s11892-008-0047-5.","journal-title":"Curr Diab Rep"},{"key":"257_CR3","doi-asserted-by":"publisher","first-page":"95103","DOI":"10.1155\/2007\/95103","volume":"2007","author":"TS Kern","year":"2007","unstructured":"Kern TS: Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007, 2007: 95103-","journal-title":"Exp Diabetes Res"},{"issue":"6","key":"257_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.preteyeres.2008.09.002","volume":"27","author":"B Wirostko","year":"2008","unstructured":"Wirostko B, Wong TY, Simo R: Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008, 27 (6): 608-621. 10.1016\/j.preteyeres.2008.09.002.","journal-title":"Prog Retin Eye Res"},{"key":"257_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/OPTH.S8980","volume":"4","author":"R Karim","year":"2010","unstructured":"Karim R, Tang B: Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol. 2010, 4: 493-517.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"257_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","volume":"248","author":"BP Nicholson","year":"2010","unstructured":"Nicholson BP, Schachat AP: A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010, 248 (7): 915-930. 10.1007\/s00417-010-1315-z.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"257_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1755-3768.2009.01580.x","volume":"87","author":"G Querques","year":"2009","unstructured":"Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND: Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol. 2009, 87 (6): 623-630. 10.1111\/j.1755-3768.2009.01580.x.","journal-title":"Acta Ophthalmol"},{"key":"257_CR8","doi-asserted-by":"crossref","first-page":"672178","DOI":"10.1155\/2009\/672178","volume":"2009","author":"G Querques","year":"2009","unstructured":"Querques G, Bux AV, Fusco AR, Iaculli C, Delle Noci N: Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema. J Ophthalmol. 2009, 2009: 672178-","journal-title":"J Ophthalmol"},{"issue":"8","key":"257_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/eye.2010.14","volume":"24","author":"D Hornan","year":"2010","unstructured":"Hornan D, Edmeades N, Krishnan R, Khan J, Lochhead J: Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. Eye (Lond). 2010, 24 (8): 1315-1319. 10.1038\/eye.2010.14.","journal-title":"Eye (Lond)"},{"issue":"15","key":"257_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","volume":"117","author":"TK Schramm","year":"2008","unstructured":"Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, et al: Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008, 117 (15): 1945-1954. 10.1161\/CIRCULATIONAHA.107.720847.","journal-title":"Circulation"},{"issue":"4","key":"257_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1161\/01.STR.0000260100.71665.2f","volume":"38","author":"CB Giorda","year":"2007","unstructured":"Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E: Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke. 2007, 38 (4): 1154-1160. 10.1161\/01.STR.0000260100.71665.2f.","journal-title":"Stroke"},{"key":"257_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2840-8-17","volume":"8","author":"M Hyvarinen","year":"2009","unstructured":"Hyvarinen M, Tuomilehto J, Laatikainen T, Soderberg S, Eliasson M, Nilsson P, Qiao Q: The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Cardiovasc Diabetol. 2009, 8: 17-10.1186\/1475-2840-8-17.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"257_CR13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1161\/STROKEAHA.106.481390","volume":"38","author":"T Jeerakathil","year":"2007","unstructured":"Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR: Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. Stroke. 2007, 38 (6): 1739-1743. 10.1161\/STROKEAHA.106.481390.","journal-title":"Stroke"},{"issue":"9733","key":"257_CR14","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010, 375 (9733): 2215-2222. 10.1016\/S0140-6736(10)60484-9.","journal-title":"Lancet"},{"issue":"4","key":"257_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339 (4): 229-234. 10.1056\/NEJM199807233390404.","journal-title":"N Engl J Med"},{"key":"257_CR16","doi-asserted-by":"crossref","unstructured":"Peripheral arterial disease in people with diabetes. Diabetes Care. 2003, 26 (12): 3333-3341.","DOI":"10.2337\/diacare.26.12.3333"},{"issue":"6","key":"257_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","volume":"113","author":"DJ D'Amico","year":"2006","unstructured":"D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B: Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006, 113 (6): 992-1001. 10.1016\/j.ophtha.2006.02.027. e1006","journal-title":"Ophthalmology"},{"issue":"12","key":"257_CR18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","volume":"92","author":"LJ Singerman","year":"2008","unstructured":"Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D: Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008, 92 (12): 1606-1611. 10.1136\/bjo.2007.132597.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"257_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1517\/14656566.9.3.499","volume":"9","author":"RS Apte","year":"2008","unstructured":"Apte RS: Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008, 9 (3): 499-508. 10.1517\/14656566.9.3.499.","journal-title":"Expert Opin Pharmacother"},{"issue":"27","key":"257_CR20","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351 (27): 2805-2816. 10.1056\/NEJMoa042760.","journal-title":"N Engl J Med"},{"key":"257_CR21","doi-asserted-by":"crossref","unstructured":"Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed). 1988, 296 (6618): 320-331.","DOI":"10.1136\/bmj.296.6618.320"},{"key":"257_CR22","doi-asserted-by":"crossref","unstructured":"Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994, 308 (6921): 81-106.","DOI":"10.1136\/bmj.308.6921.81"},{"issue":"12","key":"257_CR23","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007, 96 (12): 1788-1795. 10.1038\/sj.bjc.6603813.","journal-title":"Br J Cancer"},{"issue":"2","key":"257_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","volume":"116","author":"T Ueta","year":"2009","unstructured":"Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T: Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009, 116 (2): 362-","journal-title":"Ophthalmology"},{"issue":"3","key":"257_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/bjo.2009.178574","volume":"95","author":"C Schmucker","year":"2011","unstructured":"Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M: Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011, 95 (3): 308-317. 10.1136\/bjo.2009.178574.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"257_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3129\/i10-027","volume":"45","author":"JA Micieli","year":"2010","unstructured":"Micieli JA, Micieli A, Smith AF: Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol. 2010, 45 (3): 231-238. 10.3129\/i10-027.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"257_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","volume":"21","author":"C Schmucker","year":"2010","unstructured":"Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M: Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol. 2010, 21 (3): 218-226. 10.1097\/ICU.0b013e3283386783.","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"257_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","volume":"94","author":"K Matsuyama","year":"2010","unstructured":"Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T: Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010, 94 (9): 1215-1218. 10.1136\/bjo.2008.156810.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"257_CR29","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","volume":"114","author":"RS Apte","year":"2007","unstructured":"Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP: Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007, 114 (9): 1702-1712.","journal-title":"Ophthalmology"},{"issue":"2","key":"257_CR30","first-page":"122","volume":"115","author":"T Ishibashi","year":"2011","unstructured":"Ishibashi T: Long Term Efficacy and Safety Profile of Pegaptanib Sodium for Age-related Macular Degeneration with Choroidal Neovascularization - Evaluation of Extended Phase II Clinical Trial. Nippon Ganka Gakkai Zasshi. 2011, 115 (2): 122-133.","journal-title":"Nippon Ganka Gakkai Zasshi"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-12-37\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T12:21:10Z","timestamp":1562070070000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-12-37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-12-37","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,8]]},"article-number":"37"}}